{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T02:50:06Z","timestamp":1791859806177,"version":"4.3.4"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T00:00:00Z","timestamp":1574726400000},"content-version":"am","delay-in-days":298,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.jad.2018.11.090","type":"journal-article","created":{"date-parts":[[2018,11,13]],"date-time":"2018-11-13T12:04:58Z","timestamp":1542110698000},"page":"957-964","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Double-blind, placebo-controlled trial of pioglitazone for bipolar depression"],"prefix":"10.1016","volume":"245","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3515-3993","authenticated-orcid":false,"given":"Awais","family":"Aftab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Kemp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Ganocy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3503-7172","authenticated-orcid":false,"given":"Martha","family":"Schinagle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Conroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany","family":"Brownrigg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"D'Arcangelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9199-4543","authenticated-orcid":false,"given":"Toyomi","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Woods","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Beth","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiqin","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph R.","family":"Calabrese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keming","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2018.11.090_bib0001","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.4088\/JCP.v67n1009","article-title":"Subsyndromal depressive symptoms are associated with functional impairment in patients with bipolar disorder: results of a large, multisite study","volume":"67","author":"Altshuler","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2018.11.090_bib0002","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ajp.2015.07.017","article-title":"Emergent treatments based on the pathophysiology of bipolar disorder: a selective review","volume":"18","author":"Brady","year":"2015","journal-title":"Asian J. Psychiatr."},{"key":"10.1016\/j.jad.2018.11.090_bib0003","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1586\/ern.10.185","article-title":"Insulin dysfunction and allostatic load in bipolar disorder","volume":"11","author":"Brietzke","year":"2011","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.jad.2018.11.090_bib0004","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jpsychires.2014.08.002","article-title":"Adipokines as emerging depression biomarkers: a systematic review and meta-analysis","volume":"59","author":"Carvalho","year":"2014","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jad.2018.11.090_bib0005","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2147\/NDT.S121149","article-title":"Pioglitazone could induce remission in major depression: a meta-analysis","volume":"13","author":"Colle","year":"2017","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.jad.2018.11.090_bib0006","first-page":"49","article-title":"PPAR-gamma agonists for the treatment of major depression: a review","volume":"50","author":"Colle","year":"2017","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.jad.2018.11.090_bib0007","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1159\/000371803","article-title":"Leptin in depressive episodes: is there a difference between unipolar and bipolar depression?","volume":"101","author":"Cordas","year":"2015","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.jad.2018.11.090_bib0008","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa1010949","article-title":"Pioglitazone for diabetes prevention in impaired glucose tolerance","volume":"364","author":"DeFronzo","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jad.2018.11.090_bib0009","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1677\/joe.0.1690453","article-title":"Peroxisome proliferator-activated receptors in inflammation control","volume":"169","author":"Delerive","year":"2001","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.jad.2018.11.090_bib0010","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1080\/14737175.2016.1276284","article-title":"Is there a 'weight neutral' second-generation antipsychotic for bipolar disorder?","volume":"17","author":"Fang","year":"2017","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.jad.2018.11.090_bib0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eurpsy.2016.02.003","article-title":"Leptin in bipolar disorder: a systematic review and meta-analysis","volume":"35","author":"Fernandes","year":"2016","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.jad.2018.11.090_bib0012","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/JCP.0000000000000596","article-title":"Subjective versus objective weight gain during acute treatment with second-generation antipsychotics in schizophrenia and bipolar disorder","volume":"36","author":"Gao","year":"2016","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2018.11.090_bib0013","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.4088\/JCP.09r05535gre","article-title":"Number needed to treat to harm for discontinuation due to adverse events in the treatment of bipolar depression, major depressive disorder, and generalized anxiety disorder with atypical antipsychotics","volume":"72","author":"Gao","year":"2011","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2018.11.090_bib0014","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1007\/s12264-014-1534-0","article-title":"Important clinical features of atypical antipsychotics in acute bipolar depression that inform routine clinical care: a review of pivotal studies with number needed to treat","volume":"31","author":"Gao","year":"2015","journal-title":"Neurosci. Bull."},{"key":"10.1016\/j.jad.2018.11.090_bib0015","series-title":"ECDEU Assessment Manual for Psychopharmacology","first-page":"534","author":"Guy","year":"1976"},{"key":"10.1016\/j.jad.2018.11.090_bib0016","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/34184","article-title":"PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines","volume":"391","author":"Jiang","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.jad.2018.11.090_bib0017","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1001\/archpsyc.59.6.530","article-title":"The long-term natural history of the weekly symptomatic status of bipolar I disorder","volume":"59","author":"Judd","year":"2002","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2018.11.090_bib0018","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.2741\/2802","article-title":"Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists","volume":"13","author":"Kapadia","year":"2008","journal-title":"Front. Biosci."},{"key":"10.1016\/j.jad.2018.11.090_bib0019","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.psyneuen.2012.08.010","article-title":"Does pioglitazone improve depression through insulin-sensitization? Results of a randomized double-blind metformin-controlled trial in patients with polycystic ovarian syndrome and comorbid depression","volume":"38","author":"Kashani","year":"2013","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.jad.2018.11.090_bib0020","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.jad.2011.06.033","article-title":"Use of insulin sensitizers for the treatment of major depressive disorder: a pilot study of pioglitazone for major depression accompanied by abdominal obesity","volume":"136","author":"Kemp","year":"2012","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2018.11.090_bib0021","doi-asserted-by":"crossref","first-page":"181","DOI":"10.31887\/DCNS.2008.10.2\/dekemp","article-title":"Bipolar depression: trial-based insights to guide patient care","volume":"10","author":"Kemp","year":"2008","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.jad.2018.11.090_bib0022","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s40263-014-0158-2","article-title":"PPAR-gamma agonism as a modulator of mood: proof-of-concept for pioglitazone in bipolar depression","volume":"28","author":"Kemp","year":"2014","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jad.2018.11.090_bib0023","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1159\/000366488","article-title":"Leptin is associated with mood status and metabolic homeostasis in patients with bipolar disorder","volume":"70","author":"Lee","year":"2014","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.jad.2018.11.090_bib0024","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.psychres.2015.10.013","article-title":"Adjuvant pioglitazone for unremitted depression: clinical correlates of treatment response","volume":"230","author":"Lin","year":"2015","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.jad.2018.11.090_bib0025","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1073\/pnas.0508901103","article-title":"Leptin: a potential novel antidepressant","volume":"103","author":"Lu","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jad.2018.11.090_bib0026","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"10.1016\/j.jad.2018.11.090_bib0027","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/archgenpsychiatry.2011.12","article-title":"Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative","volume":"68","author":"Merikangas","year":"2011","journal-title":"Arch. Gen. Psychiatry"},{"issue":"Suppl 1","key":"10.1016\/j.jad.2018.11.090_bib0028","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0165-0327(14)70003-5","article-title":"The prevalence and burden of bipolar depression","volume":"169","author":"Miller","year":"2014","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2018.11.090_bib0029","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2018.11.090_bib0030","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.psyneuen.2018.05.010","article-title":"Repositioning of diabetes treatments for depressive symptoms: a systematic review and meta-analysis of clinical trials","volume":"94","author":"Moulton","year":"2018","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.jad.2018.11.090_bib0031","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/bdi.12373","article-title":"Anti-inflammatory agents in the treatment of bipolar depression: a systematic review and meta-analysis","volume":"18","author":"Rosenblat","year":"2016","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.jad.2018.11.090_bib0032","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.bbr.2011.06.011","article-title":"Antidepressant-like effect of pioglitazone in the forced swimming test in mice: the role of PPAR-gamma receptor and nitric oxide pathway","volume":"224","author":"Sadaghiani","year":"2011","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.jad.2018.11.090_bib0033","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/35007534","article-title":"Central nervous system control of food intake","volume":"404","author":"Schwartz","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.jad.2018.11.090_bib0034","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1038\/npp.2012.58","article-title":"Pioglitazone adjunctive therapy for moderate-to-severe major depressive disorder: randomized double-blind placebo-controlled trial","volume":"37","author":"Sepanjnia","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jad.2018.11.090_bib0035","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/da.1033","article-title":"Reliability and validity of a structured interview guide for the Hamilton Anxiety Rating Scale (SIGH-A)","volume":"13","author":"Shear","year":"2001","journal-title":"Depress. Anxiety"},{"issue":"Suppl 20","key":"10.1016\/j.jad.2018.11.090_bib0036","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2018.11.090_bib0037","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.neulet.2014.02.005","article-title":"Lithium decreases plasma adiponectin levels in bipolar depression","volume":"564","author":"Soeiro-de-Souza","year":"2014","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.jad.2018.11.090_bib0038","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1017\/S0033291703001107","volume":"34","author":"Trivedi","year":"2004","journal-title":"Psychol. Med."},{"key":"10.1016\/j.jad.2018.11.090_bib0039","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/da.22340","article-title":"Pioglitazone adjunctive therapy for depressive episode of bipolar disorder: a randomized, double-blind, placebo-controlled trial","volume":"32","author":"Zeinoddini","year":"2015","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.jad.2018.11.090_bib0040","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.neuroscience.2010.12.029","article-title":"Neuroprotective effects of pioglitazone in a rat model of permanent focal cerebral ischemia are associated with peroxisome proliferator-activated receptor gamma-mediated suppression of nuclear factor-kappaB signaling pathway","volume":"176","author":"Zhang","year":"2011","journal-title":"Neuroscience"}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032718316616?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032718316616?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T01:24:26Z","timestamp":1759022666000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032718316616"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":40,"alternative-id":["S0165032718316616"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2018.11.090","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Double-blind, placebo-controlled trial of pioglitazone for bipolar depression","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2018.11.090","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}